Products & Tech | Page 46 of 63

Adding Byetta to Diabetes Treatment May Reduce Risk Of Heart Failure

Results from a retrospective analysis of more than 778,000 patients showed the addition of Byetta (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings were presented by Amylin and Eli Lilly...

New Type 2 Diabetes Drug, Bydureon, Shows Positive Effect on A1c and Weight

Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the...

Inhaled Insulin, Afrezza, Does Not Increase Cardiovascular Risk

Treating type 1 and type 2 diabetes with investigational ultra rapid acting mealtime insulin Afrezza (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events according to two new studies being presented at the American Diabetes Association's...

Type 2 Diabetes Drug, Linagliptin, Receives Positive Opinion From EMA and CHMP

The European Medicines Agency's (EMA) medicinal committee issued an opinion recommending the approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta in Europe) for the treatment of adults with type 2 diabetes. If adopted by the European Commission, the drug made and distributed by Eli Lilly and Boehringer Ingelheim, will be the only...

Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe

The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes' type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients...

Long Term Use of Diabetes Drug Actos May Increase Risk of Cancer

The U.S. Food and Drug Administration (FDA) issued a safety announcement informing the public that use of the type 2 diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines...

New Type 2 Diabetes Treatment Tradjenta Now Available in U.S. Pharmacies

The new type 2 diabetes drug Tradjenta (linagliptin) is now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid following the U.S. Food and Drug Administration (FDA) approval of the drug on May 2, 2011. Tradjenta was approved as a prescription medication to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes...

Novo Nordisk Issues Letter Reminding Healthcare Professionals of Victoza Risks

Novo Nordisk issued a letter reminding healthcare professionals of important safety information about the type 2 diabetes drug Victoza (liraglutide [rDNA origin]). The letter was issued because a recent assessment of healthcare providers showed that some primary care providers are not fully aware of the serious risks associated with the use of Victoza...

Eli Lilly’s Updated Humalog(R) Label Receives FDA Approval

The U.S. Food and Drug Administration (FDA) approved Eli Lilly's supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]). Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days...

New Animas Combined CGM and Insulin Pump Receives European Approval

The Animas corporation announced that Animas Vibe, the first and only continuous glucose monitoring (CGM)-enabled insulin pump system with Dexcom G4™ CGM technology, received the CE Mark of approval. The Animas® Vibe combines the features of an Animas insulin pump with the convenience of Dexcom CGM, which is the only sensor approved for up to seven days of wear...